# Kamada Raises 2026 Outlook as Third-Quarter Revenue Climbs 11% By John Kim Canonical URL: https://www.tokenpost.com/news/business/53341 Published: 2026-11-10T21:41:37.000Z Updated: 2026-11-10T21:41:37.000Z Section: Business > Kamada is ramping up plasma collection at its Texas facilities for a three-year agreement expected to generate about $50 million. Kamada Ltd. (NASDAQ: KMDA) raised its 2026 revenue and adjusted EBITDA forecasts after third-quarter revenue rose 11% year over year, as net income and gross margin also increased. Revenue for the three months ended Sept. 30 reached $52 million, up from $47 million a year earlier. Net income rose 51% to $8 million, or $0.14 per diluted share, from $5.3 million, or $0.09 per share. Gross profit increased to $23.3 million from $19.8 million, while gross margin climbed to 45% from 42%. Higher margins on proprietary products, reflecting product and market mix, lifted gross margin. Adjusted EBITDA, a non-IFRS earnings measure, rose 30% to $15.2 million. Adjusted EBITDA is a non-IFRS measure and should not be treated as a substitute for IFRS results. Kamada raised its 2026 revenue forecast to $205 million-$208 million from $200 million-$205 million. Its adjusted EBITDA forecast increased to $52 million-$54 million from $50 million-$53 million. The new ranges’ midpoints imply year-over-year growth of 14% in revenue and 26% in adjusted EBITDA. The results followed Kamada’s previously scheduled release for Monday, Nov. 9, detailed in an [earlier notice to investors](). The company is ramping up plasma collection at its Texas facilities for a three-year supply agreement announced in July. The deal is expected to generate about $50 million in revenue, with initial commercial sales expected in the fourth quarter of 2026; those sales were included in the earlier 2026 guidance. Kamada operates three FDA-approved plasma collection centers in Beaumont, Houston and San Antonio, Texas. “We continue to ramp up plasma collection at our Texas-based facilities in support of our new three-year, approximately $50 million supply agreement,” Kamada CEO Amir London said. Kamada launched two additional biosimilar products in Israel and expects its biosimilar portfolio to generate about $10 million in annual revenue in 2028 and $20 million-$25 million by 2030. For the first nine months of 2026, revenue totaled $152.2 million, up 12% year over year, while distribution-segment revenue increased 35% to $24.1 million. Kamada projects double-digit revenue and profitability growth in 2027, with detailed guidance planned for January 2027. ## Links in this article - [earlier notice to investors](https://www.tokenpost.com/news/business/46471)